Biolojic Design Presents Promising Preclinical Data for Multibody-Drug Conjugate BD200

New data shows BD200's strong anti-tumor activity across multiple cancer models, including in resistant settings.

Apr. 17, 2026 at 7:23pm

Got story updates? Submit your updates here. ›

Biolojic Design, a biotechnology company using AI to develop multifunctional antibody-based medicines, presented new preclinical data at the American Association of Cancer Research Annual Meeting demonstrating the potent anti-tumor properties of its multibody-drug conjugate BD200. The data showed BD200 had superior uptake and cytotoxicity compared to approved drugs targeting Trop-2 or Nectin-4 alone, and exhibited strong anti-tumor activity across multiple human tumor models, including in settings where other antibody-drug conjugates were ineffective. Biolojic expects BD200 to enter clinical trials in the second half of 2026.

Why it matters

Multibody-drug conjugates like BD200 represent a novel approach to cancer treatment, with the potential to overcome limitations of current antibody-drug conjugates by more effectively targeting tumor antigen heterogeneity. The strong preclinical data for BD200 suggests it could offer enhanced anti-tumor activity and a better safety profile compared to existing therapies, addressing significant unmet needs in solid tumor oncology.

The details

BD200 is a multibody-drug conjugate that targets the tumor antigens Trop-2 and Nectin-4, which are co-expressed in various solid tumors. Unlike conventional bi-specific antibodies with fixed binding profiles, each arm of BD200 can conditionally bind to either Trop-2 or Nectin-4, helping it overcome target expression heterogeneity. This enables BD200 to deliver more of its cytotoxic payload to the tumor while reducing off-target toxicity. The preclinical data presented at AACR showed BD200 had superior uptake and cytotoxicity compared to approved drugs targeting Trop-2 or Nectin-4 alone, and demonstrated strong anti-tumor activity across multiple human tumor models, including in resistant settings where other antibody-drug conjugates were ineffective.

  • The preclinical data for BD200 was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026 in San Diego.
  • Biolojic Design expects BD200 to enter clinical trials in the second half of 2026.

The players

Biolojic Design

A biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines.

Yanay Ofran, PhD

CEO and founder of Biolojic Design.

BD200

Biolojic Design's multibody-drug conjugate that targets the tumor antigens Trop-2 and Nectin-4.

Trop-2

A protein that drives tumor progression, adhesion, and metastasis, and is co-expressed with Nectin-4 in various solid tumors.

Nectin-4

A protein that drives tumor progression, adhesion, and metastasis, and is co-expressed with Trop-2 in various solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“We're excited to share data from the first ever multibody-drug conjugate, which has the potential to transform ADC technology and, as our data suggest, lead to more efficacious and safer treatment.”

— Yanay Ofran, PhD, CEO and founder of Biolojic Design

What’s next

Biolojic Design expects BD200 to enter clinical trials in the second half of 2026.

The takeaway

The promising preclinical data for Biolojic Design's multibody-drug conjugate BD200 suggests it could offer enhanced anti-tumor activity and a better safety profile compared to existing antibody-drug conjugates, potentially transforming the treatment of solid tumors. The unique ability of BD200 to conditionally bind to multiple tumor antigens may help overcome the challenges of target expression heterogeneity that limit the effectiveness of current therapies.